ImageneBio, Inc. (IMA) stock

IMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30

$3.45−0.27 (-7.26%)

Close on Nov 12, 2026Market cap $39.16MP/E –Yield –

Earnings

ImageneBio's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report

Mar 9, 2027

Q4 FY2026 · estimated, before the open

Revenue, Q3 FY2026

–

EPS, Q3 FY2026

-$0.91

-$2.91 a year earlier

Latest guidance

None

No outlook given in releases

Quarterly results

Revenue and earnings per share from each of ImageneBio's earnings releases, newest first

Quarter	Reported	Revenue	YoY	EPS	Source
Q4 FY2026ended Dec 31, 2026	Mar 9, 2027Expected	–	–	–	–
Q3 FY2026ended Sep 30, 2026	Nov 9, 2026after the close	–	–	-$0.91	Release
Q2 FY2026ended Jun 30, 2026	Aug 5, 2026before the open	–	–	-$0.63	Release
Q1 FY2026ended Mar 31, 2026	May 7, 2026during market hours	–	–	–	Release
Q4 FY2025ended Dec 31, 2025	Mar 10, 2026before the open	–	–	–	Release
Q3 FY2025ended Sep 30, 2025	Nov 12, 2025before the open	–	–	-$2.91	Release
Q4 FY2023ended Dec 31, 2023	Jan 18, 2024during market hours	–	–	–	Release
Q3 FY2023ended Sep 30, 2023	Nov 9, 2023before the open	$1.20M	–	–	Release
Q2 FY2021ended Jun 30, 2021	Aug 12, 2021before the open	–	–	–	Filing
Q1 FY2021ended Mar 31, 2021	May 13, 2021before the open	–	–	–	Filing

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

ImageneBio has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When ImageneBio puts a forecast in an earnings release, it is listed here with the exact sentence.